LOGIN  |  REGISTER
Recursion

Pennant Appoints Suzanne Snapper as Director

May 16, 2025 | Last Trade: US$28.63 0.80 -2.72

EAGLE, Idaho, May 16, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced the appointment of Suzanne D. Snapper to its board of directors following her election by a vote of shareholders in connection with the Company’s annual shareholder meeting.

Ms. Snapper is the Chief Financial Officer of the Ensign Group, Inc. (“Ensign”) (NASDAQ: ENSG), a leading publicly-traded provider of skilled nursing services. In this role, which Ms. Snapper has held since 2009, Ms. Snapper is responsible for Ensign’s accounting, finance, information technology, tax, internal controls, investor relations, managed care, treasury and finance risk management functions. Ms. Snapper has served as a member of Ensign’s board of directors since 2022. Prior to Ensign, Ms. Snapper acquired additional invaluable experience in financial management and reporting while employed at KPMG from 1996 to 2007. Ms. Snapper is a certified public accountant.

“Suzanne is a highly skilled and experienced health care leader who will add tremendous value to our organization,” said Brent Guerisoli, Pennant’s Chief Executive Officer and Chairman. “I am excited to have the benefit of her insights on our Board. Suzanne brings cutting edge expertise in financial matters, investor relations, and more. In addition, she deeply understands the culture and operating model that Pennant shares with Ensign. She is someone I trust and admire, and I look forward to working more closely with her.”

Ms. Snapper succeeds JoAnne Stringfield, who served on Pennant’s board from 2019 to 2025. Ms. Stringfield resigned at the end of her term to pursue other interests and to facilitate Ms. Snapper’s appointment.

“We are so grateful to JoAnne for the support she has given to Pennant as a founding member of its board of directors,” said Mr. Guerisoli. “JoAnne has been a dedicated and committed director whose contributions to the Company have been significant. We thank her for her service and wish her the best in her future endeavors.”

Ms. Snapper’s appointment is effective today, May 16, 2025. She will serve as a Class III director eligible for reelection in 2028. The number of directors on Pennant’s board will remain unchanged at eight.

About Pennant:

The Pennant Group, Inc. is a holding company of independent operating subsidiaries that provide healthcare services through 137 home health and hospice agencies and 60 senior living communities located throughout Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. Each of these businesses is operated by a separate, independent operating subsidiary that has its own management, employees and assets. References herein to the consolidated "company" and "its" assets and activities, as well as the use of the terms "we," "us," "its" and similar verbiage, are not meant to imply that The Pennant Group, Inc. has direct operating assets, employees or revenue, or that any of the home health and hospice businesses, senior living communities or the Service Center are operated by the same entity. More information about Pennant is available at www.pennantgroup.com.

Contact Information

The Pennant Group, Inc.
(208) 506-6100
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page